Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in multiple cancers. However, durable antitumor responses have been observed in only a minority of patients, indicating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hack, Stephen P., Zhu, Andrew X., Wang, Yulei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674951/
https://www.ncbi.nlm.nih.gov/pubmed/33250900
http://dx.doi.org/10.3389/fimmu.2020.598877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674951/
https://www.ncbi.nlm.nih.gov/pubmed/33250900
http://dx.doi.org/10.3389/fimmu.2020.598877

Ejemplares similares